Skip to main content
Article thumbnail
Location of Repository

Regulation of Mitochondria-dependent Apoptosis in Non-Small Cell Lung Cancer: Implications for Cancer Therapy

By A. Checinska


Summary The work described in this thesis focuses on the characterization of the mechanism(s) underlying the deregulated activation of the intrinsic or mitochondrial apoptotic pathway in non-small cell lung cancer (NSCLC) cells. Apoptosis suppression might contribute to the chemoresistance often observed in NSCLC patients, and elucidation of the molecular causes of this resistance may provide clues for the development of targeted apoptosis-based therapies. In this introduction, lung cancer and current treatment regimens are described, and mechanisms responsible for chemoresistance, in particular towards cisplatin, are summarized. Furthermore, the major apoptotic pathways are presented, with a detailed description of the mitochondrial apoptotic route and its regulation by Bcl-2 family members and inhibitors of apoptosis. Finally, known mechanisms of apoptosis-dependent chemoresistance and innovative apoptosis-targeting strategies for cancer therapy are discussed.Giaccone, G. [Promotor

Topics: The role of caspases in the sensitivity of lung cancer cells to chemotherapy, Lung cancer, chemoresistance, caspase-9, apoptosome, IAPs/Smac, TUCAN
Publisher: Amsterdam: Vrije Universiteit
Year: 2007
OAI identifier:
Provided by: DSpace at VU

Suggested articles


  1. (2002). a novel anti apoptotic protein that enhances XIAP mediated activation of JNK1 and protection against apoptosis. doi
  2. (2000). A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non small cell lung cancer. Eastern Cooperative Oncology Group. doi
  3. (2005). A small molecule Smac mimic compound induces apoptosis and sensitizes TRAIL and etoposide induced apoptosis in breast cancer cells. Oncogene doi
  4. (2004). A small molecule Smac mimic potentiates TRAIL and TNF alpha mediated cell death. Science doi
  5. (2003). A unified model for apical caspase activation. Mol Cell doi
  6. (2000). Adjuvant chemotherapy following radical surgery for non small cell lung cancer: a randomized study on 70 patients. Chin Med J, doi
  7. (2004). An apoptosis inhibiting baculovirus gene with a zinc finger like motif. J Virol 1993; 67:2168 74 Curnis
  8. (2004). An inhibitor of Bcl 2 family proteins induces regression of solid tumours. Nature 2005; 2:677 81 Oost TK, Sun C, Armstrong RC et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer.
  9. (1999). Annu Rev Cell Dev Biol doi
  10. (2002). Antisense Nucleic Acid Drug Dev doi
  11. (2003). Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res
  12. (2000). Apoptosis in cancer: cause and cure. Bioassays doi
  13. (2002). Apoptosis: a link between cancer genetics and chemotherapy. Cell
  14. (1997). Bcl 2 and Bcl XL can differentially block chemotherapy induced cell death. Blood doi
  15. (2003). Bcl 2 family proteins and the role of mitochondria in apoptosis. Curr Opin Cell Biol doi
  16. (1990). Bcl 2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature doi
  17. (2001). BCL 2, BCL X(L) sequester BH3 domain only molecules preventing BAX and BAK mediated mitochondrial apoptosis. Mol Cell doi
  18. (2001). BH3 Only proteins essential initiators of apoptotic cell death. Cell 2000; 103:839 42 doi
  19. (2004). Breast cancer cells can evade apoptosis mediated selective killing by a novel small molecule inhibitor of Bcl 2. Cancer Res doi
  20. (2003). Cancer 2002; 2:48 58 Green DR. Overview: apoptotic signalling pathways in the immune system. Immunol Rev
  21. Caspase 8: igniting the death machine. Structure 1999; 7: R225 9. doi
  22. (1995). Caspase 9 and APAF 1 form an active holoenzyme. Genes Dev 1999; 13:3179 84 doi
  23. (1999). Caspase 9 can be activated without proteolytic processing. doi
  24. (2004). Chemoresistance of non small cell lung cancer. Curr Med Chem anticancer agents, 2005; 5:73 88
  25. (2005). Cisplatin is a DNA damaging antitumor compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents. doi
  26. (1998). Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell doi
  27. (2006). Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS ETR1 and HGS ETR2 and radiotherapy: enhanced effects in vitro and dose dependent growth delay in vivo. Oncogene doi
  28. (1999). Constitutive activation of Stat3 signalling confers resistance to apoptosis in human U266 myeloma cells. Immunity doi
  29. (2005). Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res, doi
  30. (2004). Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science doi
  31. (2001). DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf 1. Oncogene doi
  32. (2005). Expression and function of the apoptosis effector Apaf 1 in melanoma. Cell Death Differ doi
  33. Formation of apoptosome is initiated by cytochrome c induced dATP hydrolysis and subsequent nucleotide exchange on Apaf 1. doi
  34. (2006). Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep doi
  35. (1998). IAP family proteins suppressors of apoptosis. Genes Dev 1999; 13:239 52 Deveraux QL, Roy N, Stennicke HR et al. IAPs block apoptotic events induced by caspase 8 and cytochrome c by direct inhibition of distinct caspases.
  36. (2002). IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol. doi
  37. (2006). Inactivation of the apoptosis effector Apaf 1 in malignant melanoma. Nature 2001; 409:207 11 Soengas MS, Gerald WL, Cordon Cardo C. Apaf 1 expression in malignant melanoma. doi
  38. (2005). Isolated limb perfusion for extremity soft tissue sarcomas, in transit metastases, and other unresectable tumors: credits, debits, and future perspectives. Curr Oncol Rep 2001; 3:359 67 Ekedahl doi
  39. (2004). Kawabata A et al. Apollon ubiquitinates SMAC and caspase 9, and has an essential cytoprotection function. Nat Cell Biol doi
  40. (2002). Keeping killers on a tight leash: transcriptional and post translational control of the pro apoptotic activity of BH3 only proteins. Cell Death Differ doi
  41. (1999). Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2:594 604 Walensky LD, Kung AL, Escher I et al. Activation of apoptosis in vivo by a hydrocarbon stapled BH3 helix.
  42. (2004). Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene doi
  43. (2002). Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non small cell lung cancer. Clin Cancer Res
  44. (2001). Maintenance of caspase 3 proenzyme dormancy by an intrinsic "safety catch" regulatory tripeptide. doi
  45. (2006). Mcl 1L cleavage is involved in TRAIL R1 and TRAIL R2 mediated apoptosis induced by HGS ETR1 and HGS ETR2 human mAbs in myeloma cells. Blood doi
  46. (1999). Modulation of apoptosis signalling pathways and cell cycle regulation. Semin Oncol
  47. (2004). Multidisciplinary Management of Lung Cancer. doi
  48. (2003). p53 and drug induced apoptotic responses mediated by BH3 only proteins puma and noxa. Science doi
  49. (1993). p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell doi
  50. (1997). p53, the cellular gatekeeper for growth and division. Cell doi
  51. (2006). Preclinical characterization of AEG35156/GEM 640, a second generation antisense oligonucleotide targeting X linked inhibitor of apoptosis. Clin Cancer Res doi
  52. (2003). Predominant suppression of apoptosome by inhibitor of apoptosis protein in non small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine conjugated Smac peptide. Cancer Res
  53. (2002). Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non small cell lung cancer. doi
  54. (2002). Prognostic factor in non small cell lung cancer: a decade of progress. Chest, doi
  55. (2002). protein, a new CARD family member that regulates caspase 1 activation and apoptosis. doi
  56. (1997). Regional lymph node classification for lung cancer staging. Chest doi
  57. (2005). Regulation of Bcl 2 proteins and of the permeability of the outer mitochondrial membrane. doi
  58. (1999). RING fingers mediate ubiquitin conjugating enzyme (E2) dependent ubiquitination. doi
  59. (2002). Role for yeast inhibitor of apoptosis (IAP) like proteins in cell division. doi
  60. (2003). Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug resistant TCC in vitro. doi
  61. (2006). Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase 3. Cancer Res
  62. (2000). Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature
  63. (2000). Structure based discovery of an organic compound that binds Bcl 2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A
  64. (2002). Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. doi
  65. (2002). The Apaf 1 apoptosome: a large caspase activating complex. Biochimie doi
  66. (2006). The human anti apoptotic proteins cIAP1 and cIAP2bind but do not inhibit caspases. doi
  67. (2002). The neuronal apoptosis inhibitory protein is a direct inhibitor of caspases 3 and 7.
  68. (2005). The role of apoptosis in cancer development and treatment response. Nat Rev Cancer doi
  69. (1999). The role of p53 in tumour suppression: lessons from mouse models. Cell Mol Life Sci doi
  70. (2003). The role of the Bcl 2 protein family in cancer. Semin Cancer Biol doi
  71. (2003). Three dimensional structure of the apoptosome: implications for assembly, procaspase 9 binding, and activation. Mol Cell 2002; 9:423 32 doi
  72. (2006). TRAIL receptor targeted therapy. Future Oncol doi
  73. (2006). TUCAN/CARDINAL/CARD8 and apoptosis resistance in non small cell lung cancer cells.
  74. Untersuchungen ├╝ber die Entwicklungsgeschichte der Geburtshelferkroete (Alytes obstetricans) 1842, Jent und Gassmann,
  75. (2004). World Health Organization classification of lung tumors. doi
  76. (2001). XIAP induces cell cycle arrest and activates nuclear factor kappaB: new survival pathways disabled by caspase mediated cleavage during apoptosis of human endothelial cells. Circ Res doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.